Overview
ENVB market data
Price History
ENVB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$26.21 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.27 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -14.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.25 – $17.64 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $5.7M · P/B 0.52 · P/S 0.14.
Company News
Enveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoYBenzinga · Aug 14, 2026, 8:32 PM
8-K filing — Enveric Biosciences, Inc. (ENVB)SEC EDGAR · Aug 14, 2026, 8:15 PM
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric CandidateBenzinga · Aug 5, 2026, 1:30 PM
Enveric Biosciences Announces New Preclinical Data That Further Supports The Non-Hallucinogenic Profile Of EB-003; GloSensor Assay Findings Align With Previously Reported BRET DataBenzinga · Aug 5, 2026, 12:08 PM
Shares of psychedelic-related biotech companies are trading higher amid sympathy with AtaiBeckley after the company announced it will be acquired by Lilly in a deal worth up to $3.8 billion.Benzinga · Jul 16, 2026, 4:43 PM
Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003Benzinga · Jun 2, 2026, 12:10 PM
Enveric Biosciences Reports Preclinical Results From Preclinical In Vitro Experiments Evaluating Photoxicity Risk, Indicates No Photoreactive Potential For EB-003Benzinga · May 19, 2026, 12:10 PM
Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoYBenzinga · May 15, 2026, 12:20 PM